Drugs / CD19-TriCAR-SILK
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03910842 | Mar 2019 → Apr 2022 | leukemia, non-Hodgkin lymphoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT03790891 | Jan 2019 → Jun 2021 | non-Hodgkin lymphoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-TriCAR-SILK | “CD19-TriCAR-SILK is an Allogeneic tri-functional CAR- NK cell therapy” NCT03910842 ↗1“CD19-TriCAR-SILK is an Allogeneic tri-functional CAR-NK cell therapy” NCT03790891 ↗ |
| Modality | Cell therapy | “Allogeneic tri-functional CAR-NK cell therapy” NCT03790891 ↗ |
| Route | Intravenous | “CD19-TriCAR-T/SILK cells will be administered intravenously” NCT03790891 ↗ |
| Target | CD19 | “anti-CD19 scFv” NCT03790891 ↗ |